Evotec SE (NASDAQ:EVO - Get Free Report) shares gapped down prior to trading on Wednesday . The stock had previously closed at $4.78, but opened at $4.59. Evotec shares last traded at $4.57, with a volume of 22,157 shares trading hands.
Analyst Ratings Changes
Several research analysts have weighed in on the company. Jefferies Financial Group lowered Evotec from a "buy" rating to a "hold" rating and reduced their target price for the stock from $8.70 to $3.80 in a report on Monday, October 7th. HC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of Evotec in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $5.93.
View Our Latest Report on EVO
Evotec Trading Down 9.4 %
The company has a debt-to-equity ratio of 0.43, a quick ratio of 1.99 and a current ratio of 2.09. The business has a 50 day moving average price of $4.25 and a 200-day moving average price of $4.14.
Institutional Investors Weigh In On Evotec
A number of institutional investors and hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in Evotec by 29.7% during the third quarter. Wellington Management Group LLP now owns 2,634,434 shares of the company's stock worth $9,616,000 after purchasing an additional 602,858 shares during the period. Clear Harbor Asset Management LLC acquired a new position in Evotec in the 3rd quarter valued at about $104,000. Mediolanum International Funds Ltd bought a new position in Evotec in the 3rd quarter valued at about $512,000. Novo Holdings A S acquired a new stake in Evotec during the second quarter worth approximately $71,183,000. Finally, DCF Advisers LLC boosted its holdings in shares of Evotec by 140.5% during the second quarter. DCF Advisers LLC now owns 114,953 shares of the company's stock worth $552,000 after acquiring an additional 67,156 shares during the period. 5.81% of the stock is owned by institutional investors.
About Evotec
(
Get Free Report)
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.
See Also
Before you consider Evotec, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.
While Evotec currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
